Eli Lilly plans at least $27 billion in new U.S. manufacturing investments

Eli Lilly on Wednesday said it will invest at least $27 billion to build four new manufacturing sites in the U.S., as demand for its blockbuster weight loss and diabetes injections soars and the company develops new drugs for other conditions.

It comes as drugmakers and companies across different industries work to build goodwill with President Donald Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains. Eli Lilly made the announcement at an event in Washington, D.C. — emphasizing the political undertones of the strategy.